• Search
  • Advanced Search

Review

January 5, 2023


Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, et al.
Clin Mol Hepatol. 2023;29(2):197-205.

Hepatocellular carcinoma (HCC) is a major cause of death in many countries, including South Korea. To provide useful and sensible advice for clinical management of patients with HCC, the Korean...

Review

December 22, 2022


Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jieyi Shi, Jian Zhou, et al.
Clin Mol Hepatol. 2023;29(2):206-216.

Liver cancer is the fourth most prevalent and the second most lethal cancer in China. Hepatitis B virus (HBV) infection represents a major risk factor for hepatocellular carcinoma (HCC). Liver...

Review

December 28, 2022


Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective
Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, et al.
Clin Mol Hepatol. 2023;29(2):217-229.

Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic hepatitis B is the most common HCC etiology in our region. With the high case load,...

Review

January 30, 2023


Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, et al.
Clin Mol Hepatol. 2023;29(2):230-241.
Hepatocellular carcinoma (HCC) is the fourth most common cancer and the second leading cause of cancer-related death in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan...

Review

March 20, 2023


Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clin Mol Hepatol. 2023;29(2):242-251.

Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC...

Review

March 10, 2023


Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(2):252-262.

Hepatocellular carcinoma (HCC) is highly prevalent and the third most common cause of cancer-related death in Asia. In contrast to the West, the main etiology of HCC in many Asian...

Review

January 19, 2023


The role of different viral biomarkers on the management of chronic hepatitis B
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, et al.
Clin Mol Hepatol. 2023;29(2):263-276.

Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess...

Review

January 30, 2023


Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, et al.
Clin Mol Hepatol. 2023;29(2):277-292.
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent...

Review

February 1, 2023


Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications
Paula Fernández-Palanca, Tania Payo-Serafín, Carolina Méndez-Blanco, et al.
Clin Mol Hepatol. 2023;29(2):293-319.

Hepatocellular carcinoma (HCC) is one of the most common and deadly cancers worldwide and is characterized by complex molecular carcinogenesis. Neuropilins (NRPs) NRP1 and NRP2 are the receptors of multiple...

Review

February 1, 2023


Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang-Chin Huang, Chun-Jen Liu
Clin Mol Hepatol. 2023;29(2):320-331.

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk...

Original Article

November 21, 2022


Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
Kathryn Jane Waller, Hajar Saihi, Wenhao Li, et al.
Clin Mol Hepatol. 2023;29(2):417-432.

Background/Aims: Immune and inflammatory cells respond to multiple pathological hits in the development of nonalcoholic steatohepatitis (NASH) and fibrosis. Relatively little is known about how their type and function change...

Original Article

January 4, 2023


Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, et al.
Clin Mol Hepatol. 2023;29(2):433-452.

Background/Aims: Global distribution of dominant liver cancer aetiologies has significantly changed over the past decades. This study analyzed the updated temporal trends of liver cancer aetiologies and sociodemographic status in...

Original Article

February 1, 2023


Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, et al.
Clin Mol Hepatol. 2023;29(2):453-464.

Background/Aims: Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection. However, early cirrhosis is...

Original Article

February 20, 2023


Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions
Jing Yang, Xujiao Tang, Zhu Liang, et al.
Clin Mol Hepatol. 2023;29(2):465-481.

Background/Aims: Disrupted bile acid regulation and accumulation in the liver can contribute to progressive liver damage and fibrosis. However, the effects of bile acids on the activation of hepatic stellate...

Original Article

January 5, 2023


Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, et al.
Clin Mol Hepatol. 2023;29(2):482-495.

Background/Aims: The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in...

Original Article

March 6, 2023


Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, et al.
Clin Mol Hepatol. 2023;29(2):496-509.

Background/Aims: We used next-generation sequencing (NGS) to analyze resistance-associated substitutions (RASs) and retreatment outcomes in patients with chronic hepatitis C virus (HCV) infection who failed direct-acting antiviral agent (DAA) treatment...
Current Issue
Volume 29(2); Apr 2023

"Most viewed" articles are from the articles published during the last six months

Review
1710
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Karim Seif El Dahan, Darine Daher, Amit G. Singal
Clin Mol Hepatol. 2023;29(Suppl):S207-S219.   Published online September 14, 2022
View: 4529   Download: 114  Citations: 3
1714
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin
Clin Mol Hepatol. 2023;29(1):77-98.   Published online October 13, 2022
View: 3757   Download: 373  Citations: 4
Editorial
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Young-Joo Jin
Clin Mol Hepatol. 2023;29(2):414-416.   Published online February 28, 2023
View: 2432   Download: 48
Review
1569
Recent updates on the management of autoimmune hepatitis
Atsumasa Komori
Clin Mol Hepatol. 2021;27(1):58-69.   Published online December 10, 2020
View: 10096   Download: 838  Citations: 30
1684
Management of refractory ascites
Florence Wong
Clin Mol Hepatol. 2023;29(1):16-32.   Published online June 9, 2022
View: 3598   Download: 492
1735
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clin Mol Hepatol. 2023;29(Suppl):S17-S31.   Published online November 29, 2022
View: 2719   Download: 454  Citations: 2
Guideline
1713
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clin Mol Hepatol. 2022;28(4):583-705.   Published online October 1, 2022
View: 4147   Download: 385  Citations: 28
Original Article
1703
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients
Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani
Clin Mol Hepatol. 2023;29(1):135-145.   Published online September 5, 2022
View: 3054   Download: 245  Citations: 4
Guideline
1619
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho
Clin Mol Hepatol. 2021;27(3):363-401.   Published online June 22, 2021
View: 12930   Download: 1,088  Citations: 99
Review
1671
Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller
Clin Mol Hepatol. 2023;29(1):1-15.   Published online April 15, 2022
View: 6712   Download: 130
1691
Wnt signaling in liver regeneration, disease, and cancer
Gengyi Zou, Jae-Il Park
Clin Mol Hepatol. 2023;29(1):33-50.   Published online July 4, 2022
View: 2845   Download: 173  Citation: 1
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, Cheng-Maw Ho, Chun-Jen Liu
Clin Mol Hepatol. 2023;29(2):230-241.   Published online January 30, 2023
View: 1844   Download: 222  Citations: 4
1699
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment
Soo-Jeung Park, Young S. Hahn
Clin Mol Hepatol. 2023;29(1):65-76.   Published online August 12, 2022
View: 2826   Download: 131  Citations: 3
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan
Clin Mol Hepatol. 2023;29(2):277-292.   Published online January 30, 2023
View: 1782   Download: 267  Citations: 3
1566
Current understanding of primary biliary cholangitis
Atsushi Tanaka
Clin Mol Hepatol. 2021;27(1):1-21.   Published online December 3, 2020
View: 9111   Download: 642  Citations: 31
1759
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
Clin Mol Hepatol. 2023;29(Suppl):S286-S301.   Published online December 28, 2022
View: 1875   Download: 143  Citations: 2
Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol. 2023;29(suppl):S5-S16.   Published online December 28, 2022
View: 1841   Download: 242  Citation: 1
Original Article
1772
Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
Kathryn Jane Waller, Hajar Saihi, Wenhao Li, James Hallimond Brindley, Anja De Jong, Wing-kin Syn, Conrad Bessant, William Alazawi
Clin Mol Hepatol. 2023;29(2):417-432.   Published online November 21, 2022
View: 1723   Download: 97  Citation: 1
1700
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(1):146-162.   Published online August 19, 2022
View: 2426   Download: 179  Citations: 6
1760
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
Clin Mol Hepatol. 2023;29(2):433-452.   Published online January 4, 2023
View: 1684   Download: 139  Citations: 4
Review
1748
Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
Clin Mol Hepatol. 2023;29(Suppl):S32-S42.   Published online December 14, 2022
View: 1897   Download: 163  Citations: 5
Guideline
KASL clinical practice guidelines for management of chronic hepatitis B
Clin Mol Hepatol. 2022;28(2):276-331.   Published online April 1, 2022
View: 6835   Download: 463  Citations: 20
Review
1678
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):790-801.   Published online May 11, 2022
View: 3853   Download: 387  Citations: 23
1749
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Clin Mol Hepatol. 2023;29(Suppl):S244-S260.   Published online December 14, 2022
View: 1955   Download: 174  Citations: 2
1755
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao
Clin Mol Hepatol. 2023;29(2):206-216.   Published online December 22, 2022
View: 1793   Download: 253  Citations: 2
1692
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clin Mol Hepatol. 2022;28(3):425-472.   Published online July 1, 2022
View: 4485   Download: 264  Citations: 7
1761
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi
Clin Mol Hepatol. 2023;29(2):197-205.   Published online January 5, 2023
View: 1573   Download: 145  Citations: 3
1758
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective
Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(2):217-229.   Published online December 28, 2022
View: 1666   Download: 164  Citations: 3
1762
Nonalcoholic fatty liver disease and non-liver comorbidities
Richie Manikat, Mindie H. Nguyen
Clin Mol Hepatol. 2023;29(Suppl):s86-s102.   Published online January 5, 2023
View: 1525   Download: 110  Citations: 2
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong
Clin Mol Hepatol. 2023;29(Suppl):S171-S183.   Published online December 12, 2022
View: 1746   Download: 180  Citation: 1

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
CURRENT ISSUE
FOR CONTRIBUTORS
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 282
TOTAL : 1298969
Close layer